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Abstract
Antigen-specific T-cells are highly variable, spanning potent antiviral efficacy and damaging
auto-reactivity. In virus infections, identifying the most efficacious responses is critical to
vaccine design. However, current methods depend on indirect measures or on ex vivo
expanded CTL clones. We here describe a novel application of cytotoxic saporin-conjugated
tetramers to kill antigen-specific T-cells without significant off-target effects. The relative effi-
cacy of distinct antiviral CD8+ T-cell specificity can be directly assessed via antigen-specific
CD8+ T-cell depletion. The utility of these reagents is demonstrated here in identifying the
CD8+ T-cell specificity most effective in preventing HIV progression in HIV-infected HLA-
B*27-positive immune controllers.
Introduction
The notion of selective T-cell depletion, most frequently aiming to purge autoreactivity, has
recently gained substantial traction in the immunological field [1–8]. The development of fluo-
rescently-labeled tetrameric peptide-MHC complexes (tetramers) allowed binding and visuali-
sation of antigen-specific T-cells [9–11] and has led to the generation of modified tetramers
that are coupled to a toxin, such as a ribosome inactivating protein saporin (SAP), that can
selectively kill antigen-specific cells of interest. Being highly specific for their cognate T-cells
and rapidly internalised upon engagement of the TCR, peptide-MHC tetramers can deliver
any coupled moiety in a very selective manner [12]. The potential to cause death of selected
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target cells makes SAP-conjugated tetramers (tet-SAP) a powerful tool not only to eliminate
auto-reactive T-cells causing disease but also by which to identify antiviral T-cell specificities
that are effective in preventing disease [4].
An elegant proof-of-concept study in the mouse-LCMV model exploited the idea of SAP-
conjugated tetramers and demonstrated tetramer-mediated selective depletion of certain CD8
+ T-cells in vitro and in vivo [4]. These cytotoxic tetramers were later used in vivo in further
murine studies to delete diabetogenic T-cells [6], encephalopathogenic T-cells [5], minor
histocompatibility HY-specific T-cells to prevent organ rejection [7], or to study ‘memory
inflation’ [13].
To date, however, the tet-SAP technology has not been applied in human studies. We here
set out to demonstrate that this tool can be used to selectively deplete HIV-specific CD8+ T-
cells in vitro, and thereby to evaluate the contribution and efficacy of a particular CD8+ T-cell
specificity to viral inhibition. Although the importance of CD8+ T-cells in HIV control has
been established for some decades [14, 15], a long-standing question–and one that is critical to
HIV vaccine design–remains, namely, which of the many different HIV-specific responses are
effective in mediating effective and durable immune control of HIV infection.
Materials and methods
Study subjects
Specimens from adult subjects from the following cohorts were used in our study:
1. Thames Valley cohort [16]: chronically HIV-infected ART-naïve adults were recruited
from the Royal Berkshire Hospital, Reading, UK; Northampton General Hospital, North-
ampton, UK; Churchill Hospital, Oxford, UK; and Wycombe Hospital, High Wycombe,
UK. This study was approved by the Institutional Review Board of the University of Oxford
and all subjects provided written informed consent for participation in the study.
2. Acute HIV Infection cohort [17, 18]: acutely HIV-infected adults were recruited at the Mas-
sachusetts General Hospital, Brigham and Women’s Hospital and the Fenway Institute of
the Beth Israel Deaconess Medical Center, Boston, MA, USA. Primary infection was classi-
fied using Fiebig staging, as previously described [19]. Subject AC198 from this cohort was
studied. He is an adult Caucasian male, enrolled in 2005 during early acute infection (esti-
mated 10–15 days post-infection, Fiebig II [19]) and received six months of ART that was
ceased as part of randomly assigned treatment interruption. This study was approved by
the Massachusetts General Hospital Institutional Review Board and all subjects provided
written informed consent for participation in the study.
3. The Study of the Consequences of Protease Inhibitor Era (SCOPE) cohort [20]: chronically
HIV-infected ART-naïve adults recruited at the University of California, San Francisco,
USA. This study was approved by the Institutional Review Board of the University of Cali-
fornia, San Francisco and all subjects gave written informed consent.
HIV plasma viral load was measured by the Roche Amplicor version 1.5 assay with with
COBAS AmpliPrep or TaqMan 48 for the Acute HIV Infection cohort or with COBAS Ampli-
cor for the other cohorts. CD4+ T-cell counts were determined by flow cytometry using stan-
dard clinical protocol. CD4+ T-cell counts and viral loads were measured on clinical grounds
and the data were supplied by the Centre of Recruitment.HLA typing was performed using a
locus specific PCR amplification strategy and a heterozygous DNA sequencing methodology
for exon 2 and 3 of the class I PCR amplicon [21].
Cytotoxic tetramers for HIV-specific CTL
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Tetramer generation
Peptide-MHC tetramers conjugated to fluorophores were generated as previously descri-
bed, using streptavidin-PE or APC to tetramerise biotinylated peptide-MHC class I mono-
mers [11]. Efficiency of tetramerisation was confirmed by staining with anti-mouse Ig κ
beads (BD Biosciences) with an anti-HLA antibody, followed by tetramer staining. Cyto-
toxic saporin-conjugated tetramers were produced by the same method using streptavidin-
saporin (Advanced Targeting Systems) to tetramerise peptide-MHC monomers according
to the published approach [4]. Briefly, these modified tetramers are coupled to a toxin, ribo-
some-inactivating protein saporin (SAP), that can selectively kill antigen-specific cells of
interest and thereby evaluate the contribution of a particular CD8+ T-cell specificity to viral
inhibition [4–7, 13]. Biotinylated peptide-MHC class I monomers generated as per standard
published approach [11] were tetramerised by stepwise addition (1/10th volume every 10
minutes) of streptavidin-SAP (Advanced Targeting Systems) at a 1:1 molar ratio of biotiny-
lated MHC to biotin binding sites [22]. Between additions, tetramerisation reaction was left
on a rotor at 4˚C protected from light.
Tetramer staining
For staining with fluorescently-conjugated tetramers, 0.5-1x106 cells per stain were washed
with PBS, incubated with relevant tetramers for 30 minutes at room temperature, washed,
further incubated with fluorochrome-conjugated antibodies for 15–20 minutes at room tem-
perature in the dark and fixed in 2% formaldehyde solution at 4˚C. Controls included cells
incubated with no tetramer and with HLA-mismatched tetramers; these were used to set up
negative gates during analysis. For staining with SAP-conjugated tetramers, cells were incu-
bated with tetramers for 30 minutes at room temperature, washed, fixed and permeabilised
with BD Cytofix/Cytoperm kit (BD Biosciences) and then incubated with antibodies, includ-
ing a secondary anti-SAP antibody (Advanced Targeting Systems). Controls included cells
incubated with no tetramer, HLA-mismatched SAP-conjugated tetramers and free unconju-
gated SAP. Negative gates during analysis were set up based on no tetramer and HLA-mis-
matched tetramer stainings. Samples were analysed in FlowJo version 9.7.6 (Tree Star, Inc.)
and hierarchically gated on singlets, lymphocytes, live cells and CD3+ cells and gated on tetra-
mer-specific CD8+ cell populations. Antibodies used in these experiments: αSAP-Alexa488
(Advanced Targeting Systems); αCD3-Pacific Orange (Invitrogen); αCD3-Brilliant Violet 421,
αCD4 OKT4-APC, αCD4 OKT4-FITC and αCD8-PE/Cy7 (BioLegend); αCD8-V450 (BD Bio-
sciences); αHLA-APC (BD Biosciences); and LIVE-DEAD fixable near-IR marker (Life
Technologies).
Tetramer internalisation experiments
To establish the kinetics of tetramer interactions with human PBMCs, internalisation experi-
ments were performed as previously described [4]. Briefly, cells were incubated with tetramers
at 4˚C for 30 minutes to allow binding, further incubated at either 37˚C or 4˚C to promote or
inhibit internalisation, respectively, for up to 3 hours, stripped of external fluorescence with
0.5M NaCl/0.5M acetic acid (pH 2.5) and immediately acquired by flow cytometry.
Timecourse of cell-depletion mediated by tetramer-SAP
To establish the timecourse and efficiency of selective tetramer-mediated cell depletion,
PBMCs or expanded CD8+ T-cells were treated with tetramer-SAP (5–10 nM) for 2 hours at
37˚C in R10, washed 3 times with R10 and further cultured in R10 (PBMCs) or R10/50
Cytotoxic tetramers for HIV-specific CTL
PLOS ONE | https://doi.org/10.1371/journal.pone.0184496 October 11, 2017 3 / 13
(expanded CD8+ T-cells) [4]. Control treatments included: free SAP, HLA-mismatched tetra-
mer-SAP, tetramer-PE and no treatment. Every 24 hours aliquots of cells from each condition
were stained with the relevant fluorochrome-conjugated tetramer and analysed by flow cytom-
etry. For comparison with the conventional cell-depletion method using anti-PE magnetic
beads [23], cells were incubated with tetramer-PE for 30 minutes on ice to allow surface bind-
ing and inhibit internalisation; tetramer-PE-bound cells were then removed using anti-PE
beads (positive selection) (EasySep, StemCell Technologies) according to the manufacturer’s
protocol.
Viral inhibition assay
To evaluate the effect of tet-SAP-mediated depletion of epitope-specific CD8+ T-cells on their
antiviral capacity, we modified previously described viral inhibition assay [24] as follows. We
used HIV-permissive H9 cell line transfected with the HLA-B27:05 gene (a generous gift from
Otto Yang) as targets; controls included H9 cells expressing HLA-B57:03 or HLA-untrans-
fected. As effector cells, we treated PBMCs with a monoclonal CD3.4 antibody bi-specific for
CD3 and CD4 (the NIH AIDS Reagent Program) to eliminate CD4+ T cells and expand CD8+
T-cells [25–27]. Expanding CD8+ T-cells were cultured for 10–20 days to achieve>90% purity
and sufficient numbers. 24–48 hours prior to the inhibition assay, CD8+ T-cells were treated
with tet-SAP or a control (untreated, HLA-mismatched tet-SAP, tet-PE, free SAP) as described
above. When cell numbers allowed, cell-depletion was confirmed by tetramer staining. For the
initial setup of the inhibition assay, target cells were infected with pre-titrated NL4-3-GFP [16]
by spinoculation for 1 hour, incubated at 37˚C for 1 hour, repeatedly washed and further cul-
tured with or without effector cells at an appropriate effector to target cell ratio in duplicates or
triplicates. Every 2–3 days, the cultures were fed and stained to assess live CD4+ GFP+ cells. %
GFP+ uninfected target cells served as a background, subtracted from all values. HIV-suppres-
sive capacity was calculated at the time of the peak of viral growth as follows [24]: suppressive
capacity = log10(%GFP+ infected target cells without effector cells / %GFP+ target cells with
effector cells). Analysis was performed in GraphPad Prism for Mac OSX, 5.0c (GraphPad
Software).
ELISPOT assay
Interferon-γ ELISPOT assays were performed as previously described [28, 29]. Peptides were
generated by Schafer-N.
Sanger sequencing of proviral genome
Genomic DNA was extracted from PBMCs using QIAmp DNA Mini kit following manufactur-
er’s protocol (Qiagen). Full length HIV genome was amplified in two overlapping fragments,
purified and sequenced as previously described [30]. This was confirmed by sequencing of HIV
protein-long fragments as previously described [31]. All sequencing was done using BigDye
Terminator v3.1 Ready Reaction mix (Applied Biosystems) and analysed using Sequencher v4.8
(Gene Codes Corp.).
Results
Recognition and internalisation of conventional and cytotoxic tetramers
We first confirmed that SAP conjugation to tetramers did not compromise tetramer recogni-
tion and internalisation by cognate CD8+ T-cells. Stainings with conventional, fluorescently
labelled peptide-MHC tetramers (tet-PE or tet-APC) and with cytotoxic tetramers (tet-SAP) of
Cytotoxic tetramers for HIV-specific CTL
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the same specificity showed comparable levels of responses (S1 Fig). An example in Fig 1A and
1B illustrates that a similar level of the immunodominant Gag-KK10 (263KRWIILGLNK272)
response was detected when PBMCs from an HLA-B27:05-positive, HIV-infected donor were
stained with either KK10-PE or KK10-SAP. Visualisation of tet-SAP-specific cells required
permeabilisation and staining with an anti-SAP fluorescent antibody following incubation
with tet-SAP (Fig 1B and 1C). HLA-mismatched tetramers (in this case HLA-B07:02-specific
tetramers) showed low background staining (0.03% of CD8+ T-cells), similar to conven-
tional tetramers (Fig 1D and 1E). Free SAP, not conjugated to tetramers and therefore lacking
the means of cell entry, did not show CD8+ T-cell binding or internalisation (Fig 1F). The
kinetics of tetramer binding and internalisation was strongly temperature-dependent (Fig 1G),
consistent with murine studies [4], and reached maximum within two hours of tetramer-
PBMC incubation at 37˚C.
Tet-SAP effectively and specifically depletes cognate CD8+ T-cells
We next assessed whether cytotoxic tetramers could deplete specific populations of human
CD8+ T-cells. An illustrative example in Fig 2A, involving the same HLA-B27:05-KK10 tetra-
mers, shows staining of PBMCs with conventional KK10-PE tetramers following either no
treatment, or treatment with KK10-SAP tetramer, HLA-mismatched tetramer or free SAP.
This demonstrated that, by 24 hours post-treatment, nearly all KK10-specific cells had been
depleted by tet-SAP, and did not re-emerge later in the time course (up to 72hrs). Similar
observations were made in relation to four other SAP-conjugated tetramers, to represent a
range of different HLA class I types and to include CD8+ T-cell responses to CMV and EBV in
addition to HIV (Fig 2B).
To address the possibility that tetramer-mediated depletion of CD8+ T-cells of one specific-
ity has any off-target effects on other CD8+ T-cell specificities, in particular those restricted by
the same HLA class I molecule, we studied the impact of the HLA-B27:05-KK10 tet-SAP on
CD8+ T-cells recognising the HLA-B27:05-restricted, subdominant HIV Pol epitope KY9
(901KRKGGIGGY909) [16]. Treatment with KK10-SAP resulted in effective depletion of
KK10-specific cells, but did not affect KY9-specific cells (Fig 2C and 2D). Similarly, KY9-SAP-
mediated depletion of KY9-specific cells did not have an effect on KK10-specific cells. These
data underscore the high degree of specificity maintained by the cytotoxic tetramers.
Contribution of KK10 to immune control of HIV determined by tet-SAP
We next applied cytotoxic tetramers to determine the contribution of specific CD8+ T-cell
responses to immune control of viral infections such as HIV. To evaluate the contribution of
the HLA-B27:05-KK10 response in an HIV-infected HLA-B27:05-positive subject, we non-
specifically expanded ‘bulk’ CD8+ T-cells from PBMCs using the bi-specific monoclonal
CD3.4 antibody [25–27], and then treated them with either the KK10-tet-SAP or treatments
that did not affect the HLA-B27:05-KK10 CD8+ T-cells (no treatment, treatment with
KK10-PE tetramer or with an HLA-mismatched tet-SAP; Fig 3A). We then assessed inhibition
of HIV replication in HLA-B27:05-expressing target cells by CD8+ T-cells with or without
Gag-KK10 depletion. The example in Fig 3B and 3C illustrates that the CD8+ T-cells with
unaffected HLA-B27:05-KK10-specific cells inhibited viral replication by 3–4 log10 compared
to the KK10-depleted CD8+ T-cells that lost the inhibitory capacity. Of note, treatment with
KK10-PE tetramer resulted in a lower percentage of KK10-specific cells being detectable by
tetramer staining 48 hours following the treatment, which was likely caused by the transient
loss of their capacity to efficiently bind tetramers–a normal characteristic of CD8+ T-cell acti-
vation [32]. Importantly, however, KK10-PE treatment did not impact T-cell suppressive
Cytotoxic tetramers for HIV-specific CTL
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capacity, whereas KK10-SAP treatment substantially reduced viral inhibition (Fig 3B and 3C).
These results strongly suggest that the KK10-specific cells had indeed been depleted by the
Fig 1. Recognition and internalisation of conventional and cytotoxic tetramers. (A-F) Representative
dot plots of PBMC staining in an HIV-infected HLA-B*27:05-positive subject with conventional fluorescently
labeled tetramer HLA-B*27:05-Gag-KK10-PE (A) or SAP-coupled HLA-B*27:05-Gag-KK10-SAP tetramer,
detected with a secondary Alexa Fluor 488 anti-SAP antibody in permeabilised (B) or not permeabilised (C)
cells. Absence of non-specific binding of HLA-mismatched tet-PE (D) and tet-SAP (E) and free unconjugated
SAP (F) is shown. Gated on live CD3+ cells around CD8+tet+ cells; numbers indicate % tet+ cells (of CD8+).
(G) Kinetics of tetramer binding and internalisation, determined by measurements of total and internal
tetramer fluorescence in cells at internalisation-promoting (37˚C) or internalisation-inhibiting (4˚C) conditions.
No further increase in internal fluorescence is observed after 90–120 minutes of internalisation time,
suggesting that nearly all cognate metabolically active (37˚C) CD8+ T-cells have internalised the tetramer.
PBMC from an HIV-negative healthy donor with an EBV-HLA-A*02:01-GL9 response were used here. ‘Total
tet-PE’ = surface-bound and internal tetramer fluorescence measured in cells not stripped of any surface-
bound tetramer; ‘internal tet-PE’ = internal tetramer fluorescence measured in acid-stripped cells. A-F,
representative of 8 independent experiments with PBMC from different donors. G, representative of 2
independent experiments with cells from two individuals.
https://doi.org/10.1371/journal.pone.0184496.g001
Cytotoxic tetramers for HIV-specific CTL
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cytotoxic KK10-SAP rather than become refractory to tetramer-PE binding and thus undetect-
able by tetramer staining. Additionally, as we demonstrated earlier, the potent toxic tetramer
had been internalised (Fig 1) and no rebound KK10-specific T-cell population re-emerged for
up to 72 hours post-treatment (Fig 2A and 2B).
In a separate experiment, we ran the same tet-SAP depletion procedure in parallel with
depletion using anti-PE magnetic beads[23] (Fig 3D–3F). This showed that depletion effi-
ciency and loss of viral inhibition were similar irrespective of the method of depletion (see Dis-
cussion below).
Fig 2. Tet-SAP effectively and specifically depletes cognate CD8+ T-cells. (A) Representative dot plots of a time course, showing
depletion of HIV HLA-B*27:05-Gag-KK10-specific CD8+ T-cells mediated by KK10-SAP. At time -2 hours, cells were left untreated or
treated with KK10-SAP, mismatch-SAP or free SAP for 2 hours at 37˚C, washed and left in media (time = 0 hours). Every 24 hours aliquots
of cells from each condition were stained with the relevant fluorochrome-conjugated tetramer and analysed by flow cytometry. Gated on live
CD3+ cells around CD8+tet+ cells; numbers indicate % tet+ cells (of CD8+) assessed at indicated times after treatment. (B) Graphical
representation of 4 depletion time courses (performed as in A) with tet-SAP of different HIV, CMV and EBV specificities and restricted by
different HLA class I molecules using cells from different individuals with the corresponding specificities. At time -2 hours cells were treated
with tetramer-SAP of interest (red lines and symbols): HIV HLA-B*27:05 KK10-SAP (top left), CMV HLA-B*07:02 TM10-SAP (top right), HIV
HLA-A*02:01 GL9-SAP (bottom left), or EBV HLA-A*02:01 GL9-SAP (bottom right). Controls included: untreated cells (black lines and
symbols), treated with mismatch-SAP tetramer (blue lines and symbols; when sufficient cell numbers were present), or treated with free SAP
(green lines and symbols, when sufficient cell numbers were present). % tet+ cells is normalised to baseline pre-treatment levels (time =
-2h). Tx = treatment. (C,D) KK10-SAP-mediated depletion (assessed 48 hours post-treatment) of HLA-B*27:05-restricted KK10-specific
CD8+ T-cells does not have an off-target effect on HLA-B*27:05-restricted KY9-specific CD8+ T-cells, while KY9-SAP-mediated elimination
of KY9-specific cells does not affect KK10-specific cells. A,B, representative of at least 10 separate experiments with cells from different
individuals with different HLA types and with tetramers of different specificities. C,D, representative of 3 independent experiments with cells
from different HIV-positive HLA-B*27:05-positive donors.
https://doi.org/10.1371/journal.pone.0184496.g002
Cytotoxic tetramers for HIV-specific CTL
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Definition of antiviral efficacy of different CD8+ T-cell responses using
tet-SAP
We next employed the tet-SAP reagents to compare simultaneously HIV-suppressive capacity of
several CD8+ T-cell specificities following this approach (S2 Fig). We used samples from an
HLA-B27:05-positive HIV-infected donor who initially controlled viraemia and had three wild-
type HLA-B27-restricted dominant responses, as determined by IFN-γ ELISPOT assays and con-
firmed by tetramer staining (Fig 4A–4C): Gag-KK10, Pol-KY9 and Vpr-VL9 (31VRHFPRPWL39).
Fig 3. Contribution of KK10 to immune control of HIV determined by tet-SAP. Panels A-C and D-F show
results with cells from two different HIV-infected HLA-B*27:05-positive donors. (A) Tetramer staining 48h
post-treatment with KK10-SAP to confirm depletion of KK10-specific cells. Gated on live CD3+ cells around
CD8+tet+ cells; numbers indicate % tet+ cells (of CD8+). (B) Viral replication in HLA-B*27:05-expressing H9
cells without or with added untreated bulk, KK10-SAP-treated, KK10-PE-treated or mismatch-tet-SAP-treated
CD8+ T-cells. Infected cells were measured by NL4-3-GFP expression. (C) Suppressive capacity of bulk,
KK10-SAP-treated or mismatch SAP-treated CD8+ T-cells. (D) Tetramer staining to confirm KK10-SAP-
mediated depletion of KK10-specific CD8+ T-cells (48 hours post-treatment) or depletion of KK10-PE-stained
cells with anti-PE magnetic beads. (E) Viral replication (as in B) in H9-HLA-B*27:05-positive infected target
cells alone or with bulk, KK10-SAP-treated or KK10-bead-depleted CD8+ T-cells. (F) Suppressive capacity of
bulk, KK10-SAP-treated or KK10-bead-depleted CD8+ T-cells. B,C,E,F, error bars represent s.e.m.
Represents 2 separate experiments with two HLA-B*27:05-positive donors.
https://doi.org/10.1371/journal.pone.0184496.g003
Cytotoxic tetramers for HIV-specific CTL
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Responses to the wild-type epitopes diminished over time, while viraemia progressively increased
and well-characterised HLA-B27-associated mutations emerged in the dominant responses (Fig
4D). Viral sequence encoding the Vpr epitope was not available for the earliest timepoint, but the
R32K escape mutant present at months 39 and 78 is characteristically selected specifically in
HLA-B27-positive subjects [33].
We next evaluated the impact on viral inhibition of tet-SAP-mediated depletion of CD8+
T-cell responses present, studying two timepoints, 4 and 8 years after infection. At 4 years (48
months) post-infection, Pol-KY9 and Vpr-VL9 depletion made little difference to viral replica-
tion, while Gag-KK10 depletion significantly attenuated the ability of CD8+ T-cells to suppress
viral replication, suggesting that the majority of bulk CD8+ T-cell-mediated inhibition was
Gag-KK10-specific (Fig 4E–4G). At 8 years (96 months) post-infection (Fig 4H–4J), the contri-
bution of the Pol-KY9 response to inhibition of viral replication was lost altogether; Vpr-VL9
Fig 4. Definition of antiviral efficacy of different CD8+ T-cell responses using tet-SAP. All panels show data from one HIV-infected
HLA-B*27:05-positive subject. (A) Viral loads, CD4+ T-cell counts with timepoints of assays indicated. (B) IFN-γ ELISPOT CD8+ T-cell
responses to HLA-B*27-restricted optimal epitopes. Only responses >50 SFC/106 PBMC are shown. (C) Frequency of antigen-specific
cells of three dominant specificities determined by tetramer staining. (D) Proviral sequences of the three dominant responses. Known
HLA-B*27:05-associated footprints and the significance of the associations (q value) are shown [33]. Nd, not done. (E-G) Results from
timepoint 48 months post-infection; (H-J) results from timepoint 96 months post-infecition. (E,H) Dot plots showing tetramer staining of
existing in this donor HLA-B*27:05-restricted responses at the timepoint assayed. Gated on live CD3+ cells around CD8+tet+ cells;
numbers indicate % tet+ cells (of CD8+). (F,I) Viral replication in H9-HLA-B*27:05-positive infected target cells alone or with bulk CD8+ T-
cells or CD8+ T-cells depleted of a particular specificity with tet-SAP. Infected cells were measured by NL4-3-GFP expression. (G,H)
Suppressive capacity of bulk or tet-SAP-depleted CD8+ T-cells. F,G,I,J, error bars represent s.e.m. G,J, ANOVA with Dunnett’s Multiple
comparisons test to compare suppressive capacity of bulk versus tet-SAP-treated CD8+ T-cells. *p<0.05, **p<0.01, ***p<0.001.
https://doi.org/10.1371/journal.pone.0184496.g004
Cytotoxic tetramers for HIV-specific CTL
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continued not to contribute significantly to viral inhibition, and the Gag-KK10-specific cells
contributed the most. Of note, the Gag-KK10 effect was seen with both the wild-type-specific
and mutant L268M-specific tet-SAP mediated depletion (Fig 4G and 4J). This can be explained
by cross-recognition of the variant by the wild-type-specific cells that are highly effective against
both wild-type and L268M viruses, express an anti-apoptotic phenotype and are long-lived.[34,
35] Although in this case the subject initiated ART through choice after 9 years of infection,
viral load was well contained for much of this time at<2,000 copies/ml, and absolute CD4
counts were maintained at high levels of 500–700 cells/mm3 until ART intervention. This is rep-
resentative of 2 similar experiments involving HLA-B27:05-positive HIV-infected individuals,
showing that in subjects with low viral loads (e.g. 73 copies/ml, 518 copies/ml), inhibition of
viral replication was highly dependent upon the Gag-KK10 response (S3 Fig).
Discussion
In summary, we here show, for the first time, that cytotoxic saporin-conjugated tetramers can
be used in in vitro studies with human cells. These tetramers bind and are internalised by cog-
nate CD8+ T-cells, resulting in their effective elimination by as little as 24 hours. We did not
observe an off-target effect and found that the tet-SAP approach is considerably simpler and
less time-consuming than the conventional method using magnetic beads, especially if more
than one CD8+ T-cell specificity is being assessed. These reagents can facilitate identification
of effective HIV-specific CD8+ T-cell responses that could be induced by a successful vaccine,
and can also be used in other viral infections such as CMV or HCV. Finally, as shown in
murine studies [4], saporin-conjugated tetramers have the potential for in vivo depletions to be
undertaken immunotherapeutically in humans.
Supporting information
S1 Fig. Similar levels of CD8+ T-cell responses are detected with both conventional tet-PE
and tet-SAP. Spearman correlation of stainings of PBMC from 8 different donors with tetra-
mers of different specificities and restricted by different HLA types.
(TIFF)
S2 Fig. Workflow of the method to assess anti-HIV efficacy of different CD8+ T-cell speci-
ficities in human cells using tet-SAP. The proposed method consists of four main steps:
1. Identify CD8+ T-cell responses by IFN-γ ELISPOT and/or tetramer staining.
2. Expand CD8+ T-cells with bi-specific CD3.4 monoclonal antibody and confirm targeted
specificities by tetramer staining
2.1. Include an anti-CD4 antibody in the panel to assess CD8+ T-cell purity.
2.2. Use this period to generate SAP-conjugated tetramers.
2.3. Prepare target cells: (i) if using HIV-permissive cell lines (e.g. H9, U937, T1), start the
cultures a week before infection; (ii) if using primary CD4+ T cells, start their activation
3–4 days before superinfection.
3. Remove desired specificities with tet-SAP and confirm by tetramer staining. Include con-
trols (HLA-mismatched tet-SAP, free SAP).
4. Perform viral inhibition assay using tet-SAP-treated CTL as effector cells. Use intracellular Gag-
p24 staining or ELISA as a read-out if the virus used for infection does not have a GFP reporter.
(TIFF)
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S3 Fig. Examples of HIV-infected HLA-B27:05-positive individuals with low viral loads in
whom control of viral replication was dependant on Gg-KK10 response. Panels A,B show
data for an HLA-B27:05-positive controller with viral load of 73 copies/ml; panels C,D show
data for another HLA-B27:05-positive controller with viral load of 518 copies/ml. (A,C) Viral
replication in H9-HLA-B27:05-positive infected target cells alone or with bulk CD8+ T-cells or
CD8+ T-cells depleted of Gag-KK10 specificity with tet-SAP. Infected cells were measured by
NL4-3-GFP expression. (B,D) Suppressive capacity of bulk or KK10-tet-SAP-depleted CD8+
T-cells. Error bars represent s.e.m.
(TIFF)
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